 Daisy Alapat
Concepts (249)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Myeloma | 28 | 2024 | 2998 | 1.800 |
Why?
| | Flow Cytometry | 5 | 2018 | 474 | 0.870 |
Why?
| | Immunoglobulins | 2 | 2018 | 81 | 0.690 |
Why?
| | Immunoglobulin kappa-Chains | 2 | 2016 | 20 | 0.630 |
Why?
| | Bone Marrow | 7 | 2022 | 363 | 0.580 |
Why?
| | DNA, Neoplasm | 1 | 2018 | 143 | 0.560 |
Why?
| | Hematopoietic Stem Cell Transplantation | 4 | 2024 | 578 | 0.550 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 2 | 2015 | 90 | 0.530 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2016 | 46 | 0.510 |
Why?
| | Immunoglobulin lambda-Chains | 1 | 2015 | 14 | 0.500 |
Why?
| | Gene Rearrangement, B-Lymphocyte | 1 | 2015 | 5 | 0.480 |
Why?
| | Receptors, Antigen, B-Cell | 1 | 2015 | 7 | 0.480 |
Why?
| | Plasma Cells | 2 | 2016 | 221 | 0.460 |
Why?
| | Tumor Microenvironment | 4 | 2024 | 222 | 0.450 |
Why?
| | Neoplasm, Residual | 5 | 2022 | 160 | 0.440 |
Why?
| | Plasmacytoma | 3 | 2022 | 42 | 0.390 |
Why?
| | Cell Differentiation | 1 | 2015 | 640 | 0.390 |
Why?
| | Humans | 48 | 2025 | 50503 | 0.390 |
Why?
| | Lymphoma, Mantle-Cell | 1 | 2012 | 14 | 0.390 |
Why?
| | Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2012 | 11 | 0.380 |
Why?
| | Carcinoembryonic Antigen | 1 | 2011 | 12 | 0.370 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2024 | 112 | 0.360 |
Why?
| | Calcitonin | 1 | 2011 | 30 | 0.360 |
Why?
| | Antigens, CD | 1 | 2012 | 222 | 0.350 |
Why?
| | Carcinoma | 1 | 2011 | 137 | 0.330 |
Why?
| | Myogenin | 1 | 2008 | 4 | 0.310 |
Why?
| | Muscle Fibers, Slow-Twitch | 1 | 2008 | 12 | 0.310 |
Why?
| | Muscle Fibers, Fast-Twitch | 1 | 2008 | 14 | 0.310 |
Why?
| | Paraproteinemias | 2 | 2022 | 72 | 0.290 |
Why?
| | Middle Aged | 18 | 2025 | 12611 | 0.290 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1000 | 0.280 |
Why?
| | Neoplasms, Second Primary | 2 | 2019 | 74 | 0.260 |
Why?
| | Prognosis | 7 | 2024 | 1978 | 0.250 |
Why?
| | Gene Expression Profiling | 3 | 2016 | 1025 | 0.250 |
Why?
| | Treatment Outcome | 10 | 2022 | 5283 | 0.240 |
Why?
| | Pancytopenia | 3 | 2016 | 37 | 0.230 |
Why?
| | Female | 21 | 2025 | 27081 | 0.220 |
Why?
| | Male | 18 | 2025 | 25907 | 0.220 |
Why?
| | Aged | 16 | 2025 | 9741 | 0.210 |
Why?
| | Gastrointestinal Neoplasms | 1 | 2022 | 40 | 0.200 |
Why?
| | Embolization, Therapeutic | 2 | 2021 | 88 | 0.190 |
Why?
| | Neoplasms, Plasma Cell | 2 | 2020 | 36 | 0.190 |
Why?
| | Thrombocytopenia | 1 | 2022 | 81 | 0.190 |
Why?
| | Chromosome Deletion | 2 | 2023 | 134 | 0.180 |
Why?
| | Cryosurgery | 1 | 2021 | 36 | 0.180 |
Why?
| | Skin Neoplasms | 2 | 2016 | 491 | 0.180 |
Why?
| | Transplantation, Autologous | 4 | 2024 | 481 | 0.170 |
Why?
| | Combined Modality Therapy | 1 | 2021 | 641 | 0.160 |
Why?
| | Ploidies | 1 | 2018 | 11 | 0.150 |
Why?
| | Phenotype | 2 | 2025 | 739 | 0.150 |
Why?
| | Hematopoietic Stem Cells | 1 | 2019 | 197 | 0.150 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2019 | 181 | 0.150 |
Why?
| | Kidney Diseases | 1 | 2020 | 213 | 0.150 |
Why?
| | Herpesvirus 8, Human | 1 | 2019 | 97 | 0.140 |
Why?
| | Sarcoma, Myeloid | 1 | 2017 | 20 | 0.140 |
Why?
| | Chromosomes, Human, Pair 17 | 1 | 2017 | 34 | 0.140 |
Why?
| | Immunohistochemistry | 3 | 2016 | 957 | 0.140 |
Why?
| | Lymph Nodes | 2 | 2019 | 257 | 0.140 |
Why?
| | Amyloidosis | 2 | 2016 | 81 | 0.140 |
Why?
| | Cell Cycle | 1 | 2018 | 226 | 0.130 |
Why?
| | CA-125 Antigen | 1 | 2016 | 16 | 0.130 |
Why?
| | Registries | 3 | 2025 | 563 | 0.130 |
Why?
| | Skin Diseases, Infectious | 1 | 2016 | 7 | 0.130 |
Why?
| | Leukemia, Promyelocytic, Acute | 1 | 2016 | 11 | 0.130 |
Why?
| | Anemia, Aplastic | 1 | 2016 | 11 | 0.130 |
Why?
| | Myeloproliferative Disorders | 1 | 2016 | 28 | 0.130 |
Why?
| | Adult | 9 | 2025 | 13577 | 0.130 |
Why?
| | Electrophoresis, Capillary | 1 | 2015 | 10 | 0.120 |
Why?
| | In Situ Hybridization | 1 | 2015 | 66 | 0.120 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2017 | 213 | 0.120 |
Why?
| | V(D)J Recombination | 1 | 2015 | 4 | 0.120 |
Why?
| | Immunophenotyping | 1 | 2015 | 105 | 0.120 |
Why?
| | RNA, Messenger | 2 | 2015 | 1089 | 0.120 |
Why?
| | Diagnosis, Differential | 3 | 2016 | 1033 | 0.120 |
Why?
| | Fatal Outcome | 1 | 2015 | 197 | 0.120 |
Why?
| | Bone Marrow Transplantation | 2 | 2022 | 136 | 0.110 |
Why?
| | Immunoglobulin Light Chains | 1 | 2015 | 84 | 0.110 |
Why?
| | Prealbumin | 1 | 2014 | 21 | 0.110 |
Why?
| | Bone Marrow Neoplasms | 1 | 2014 | 13 | 0.110 |
Why?
| | Neoplasm Proteins | 1 | 2016 | 320 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2015 | 449 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2014 | 47 | 0.110 |
Why?
| | Parvoviridae Infections | 1 | 2013 | 20 | 0.110 |
Why?
| | Parvovirus B19, Human | 1 | 2013 | 17 | 0.110 |
Why?
| | Partial Thromboplastin Time | 1 | 2012 | 12 | 0.100 |
Why?
| | Prothrombin Time | 1 | 2012 | 18 | 0.100 |
Why?
| | Cardiomyopathies | 1 | 2014 | 120 | 0.100 |
Why?
| | Afibrinogenemia | 1 | 2012 | 5 | 0.100 |
Why?
| | Predictive Value of Tests | 1 | 2015 | 930 | 0.100 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2013 | 65 | 0.100 |
Why?
| | Plasma Exchange | 1 | 2012 | 25 | 0.100 |
Why?
| | Retroperitoneal Neoplasms | 1 | 2012 | 17 | 0.100 |
Why?
| | Glycoproteins | 1 | 2012 | 116 | 0.100 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2016 | 833 | 0.100 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2012 | 8 | 0.100 |
Why?
| | Histoplasma | 1 | 2011 | 23 | 0.090 |
Why?
| | Antigens, Fungal | 1 | 2011 | 19 | 0.090 |
Why?
| | Longitudinal Studies | 2 | 2024 | 735 | 0.090 |
Why?
| | Immunoenzyme Techniques | 1 | 2011 | 137 | 0.090 |
Why?
| | Hepatitis C | 1 | 2012 | 80 | 0.090 |
Why?
| | Histoplasmosis | 1 | 2011 | 44 | 0.090 |
Why?
| | In Situ Hybridization, Fluorescence | 3 | 2023 | 231 | 0.090 |
Why?
| | Carcinoma, Neuroendocrine | 1 | 2011 | 23 | 0.090 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2016 | 1372 | 0.090 |
Why?
| | Splenic Neoplasms | 1 | 2009 | 2 | 0.080 |
Why?
| | Disease Progression | 3 | 2022 | 829 | 0.080 |
Why?
| | Gene Expression | 1 | 2012 | 610 | 0.080 |
Why?
| | Thyroid Neoplasms | 1 | 2011 | 112 | 0.080 |
Why?
| | Myelodysplastic Syndromes | 1 | 2009 | 78 | 0.080 |
Why?
| | Retrospective Studies | 4 | 2024 | 6263 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 95 | 0.080 |
Why?
| | Hemangioma | 1 | 2009 | 83 | 0.080 |
Why?
| | HIV Infections | 1 | 2012 | 352 | 0.070 |
Why?
| | Aged, 80 and over | 4 | 2019 | 3226 | 0.070 |
Why?
| | Tomography, X-Ray Computed | 3 | 2023 | 1164 | 0.070 |
Why?
| | Survival Analysis | 2 | 2021 | 661 | 0.070 |
Why?
| | Cells, Cultured | 2 | 2008 | 1571 | 0.070 |
Why?
| | Protein Processing, Post-Translational | 1 | 2008 | 156 | 0.070 |
Why?
| | Stem Cell Transplantation | 2 | 2022 | 179 | 0.070 |
Why?
| | Graft vs Host Disease | 1 | 2007 | 84 | 0.070 |
Why?
| | Adolescent | 2 | 2025 | 6443 | 0.070 |
Why?
| | Positron-Emission Tomography | 2 | 2021 | 292 | 0.070 |
Why?
| | Muscle Proteins | 1 | 2008 | 320 | 0.060 |
Why?
| | Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2005 | 32 | 0.060 |
Why?
| | Semaphorin-3A | 1 | 2004 | 2 | 0.060 |
Why?
| | Nerve Degeneration | 1 | 2004 | 25 | 0.060 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2005 | 93 | 0.060 |
Why?
| | Antineoplastic Agents | 1 | 2013 | 1172 | 0.060 |
Why?
| | Acid Anhydride Hydrolases | 1 | 2004 | 14 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 49 | 0.060 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 50 | 0.060 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2005 | 131 | 0.060 |
Why?
| | Imidazoles | 1 | 2005 | 127 | 0.060 |
Why?
| | Killer Cells, Natural | 1 | 2024 | 106 | 0.060 |
Why?
| | Ferritins | 1 | 2024 | 30 | 0.060 |
Why?
| | Pyridines | 1 | 2005 | 131 | 0.060 |
Why?
| | Gene Expression Regulation | 1 | 2008 | 955 | 0.060 |
Why?
| | Cost of Illness | 1 | 2024 | 114 | 0.060 |
Why?
| | Myeloid Progenitor Cells | 1 | 2023 | 17 | 0.060 |
Why?
| | Pyrimidines | 1 | 2005 | 191 | 0.050 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2024 | 125 | 0.050 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 99 | 0.050 |
Why?
| | Enzyme Inhibitors | 1 | 2005 | 377 | 0.050 |
Why?
| | Hippocampus | 1 | 2004 | 222 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 92 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2019 | 1156 | 0.050 |
Why?
| | Cohort Studies | 2 | 2020 | 1452 | 0.050 |
Why?
| | Chromosome Aberrations | 1 | 2023 | 280 | 0.050 |
Why?
| | Dexamethasone | 1 | 2024 | 432 | 0.050 |
Why?
| | Mediastinum | 1 | 2021 | 21 | 0.050 |
Why?
| | Gastrointestinal Tract | 1 | 2022 | 103 | 0.050 |
Why?
| | Fever | 1 | 2022 | 112 | 0.050 |
Why?
| | Vincristine | 1 | 2021 | 82 | 0.050 |
Why?
| | T-Lymphocytes | 1 | 2023 | 325 | 0.050 |
Why?
| | Neurons | 1 | 2004 | 452 | 0.050 |
Why?
| | Axilla | 1 | 2021 | 91 | 0.050 |
Why?
| | Prednisone | 1 | 2021 | 101 | 0.050 |
Why?
| | Pelvis | 1 | 2021 | 66 | 0.050 |
Why?
| | Alzheimer Disease | 1 | 2004 | 316 | 0.050 |
Why?
| | Time Factors | 2 | 2017 | 2935 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2021 | 168 | 0.040 |
Why?
| | Signal Transduction | 2 | 2004 | 1624 | 0.040 |
Why?
| | Radiopharmaceuticals | 1 | 2021 | 204 | 0.040 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2021 | 189 | 0.040 |
Why?
| | Tumor Burden | 1 | 2020 | 130 | 0.040 |
Why?
| | Mice | 3 | 2023 | 5687 | 0.040 |
Why?
| | Hospitalization | 1 | 2024 | 675 | 0.040 |
Why?
| | Antibodies, Monoclonal | 1 | 2023 | 462 | 0.040 |
Why?
| | Doxorubicin | 1 | 2021 | 236 | 0.040 |
Why?
| | False Negative Reactions | 1 | 2019 | 29 | 0.040 |
Why?
| | Cell Line, Tumor | 1 | 2023 | 1398 | 0.040 |
Why?
| | Herpesvirus 4, Human | 1 | 2019 | 37 | 0.040 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2019 | 30 | 0.040 |
Why?
| | Phosphorylation | 3 | 2005 | 525 | 0.040 |
Why?
| | Herpesviridae Infections | 1 | 2019 | 54 | 0.040 |
Why?
| | Genome, Viral | 1 | 2019 | 79 | 0.040 |
Why?
| | Virus Diseases | 1 | 2019 | 42 | 0.040 |
Why?
| | DNA, Viral | 1 | 2019 | 136 | 0.040 |
Why?
| | Follow-Up Studies | 1 | 2024 | 2242 | 0.040 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2022 | 629 | 0.040 |
Why?
| | Liver | 1 | 2022 | 1132 | 0.030 |
Why?
| | Scleromyxedema | 1 | 2016 | 4 | 0.030 |
Why?
| | Schnitzler Syndrome | 1 | 2016 | 4 | 0.030 |
Why?
| | Cryoglobulinemia | 1 | 2016 | 13 | 0.030 |
Why?
| | Xanthomatosis | 1 | 2016 | 10 | 0.030 |
Why?
| | Asymptomatic Diseases | 1 | 2016 | 37 | 0.030 |
Why?
| | POEMS Syndrome | 1 | 2016 | 32 | 0.030 |
Why?
| | Melphalan | 1 | 2016 | 178 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2016 | 444 | 0.030 |
Why?
| | Young Adult | 1 | 2025 | 4102 | 0.030 |
Why?
| | Animals | 3 | 2023 | 13124 | 0.030 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 181 | 0.030 |
Why?
| | Reed-Sternberg Cells | 1 | 2014 | 2 | 0.030 |
Why?
| | HIV Seronegativity | 1 | 2014 | 3 | 0.030 |
Why?
| | Karyotype | 1 | 2014 | 17 | 0.030 |
Why?
| | Fusion Proteins, bcr-abl | 1 | 2014 | 17 | 0.030 |
Why?
| | Thalidomide | 1 | 2016 | 378 | 0.030 |
Why?
| | Cell Division | 2 | 2005 | 291 | 0.030 |
Why?
| | Heterozygote | 1 | 2014 | 83 | 0.030 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2014 | 45 | 0.030 |
Why?
| | Mutation | 1 | 2019 | 1280 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 572 | 0.030 |
Why?
| | Remission Induction | 1 | 2014 | 208 | 0.030 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2015 | 405 | 0.030 |
Why?
| | Fibrinogen | 1 | 2012 | 32 | 0.030 |
Why?
| | Risk Assessment | 1 | 2017 | 1270 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2012 | 60 | 0.030 |
Why?
| | Survival Rate | 1 | 2015 | 909 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2015 | 746 | 0.020 |
Why?
| | Reference Values | 1 | 2012 | 307 | 0.020 |
Why?
| | Biopsy | 1 | 2014 | 588 | 0.020 |
Why?
| | Antibodies, Fungal | 1 | 2011 | 2 | 0.020 |
Why?
| | Mycological Typing Techniques | 1 | 2011 | 3 | 0.020 |
Why?
| | Cross Reactions | 1 | 2011 | 39 | 0.020 |
Why?
| | Lung Diseases, Fungal | 1 | 2011 | 19 | 0.020 |
Why?
| | Immunocompromised Host | 1 | 2011 | 119 | 0.020 |
Why?
| | Splenectomy | 1 | 2009 | 34 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2012 | 978 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2011 | 859 | 0.020 |
Why?
| | Blood Transfusion | 1 | 2009 | 129 | 0.020 |
Why?
| | Transplantation, Isogeneic | 1 | 2007 | 2 | 0.020 |
Why?
| | Laparoscopy | 1 | 2009 | 173 | 0.020 |
Why?
| | Mice, Inbred C3H | 1 | 2007 | 85 | 0.020 |
Why?
| | Cyclosporine | 1 | 2007 | 66 | 0.020 |
Why?
| | Mice, SCID | 1 | 2007 | 178 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 1548 | 0.020 |
Why?
| | Models, Animal | 1 | 2007 | 227 | 0.020 |
Why?
| | Immunosuppressive Agents | 1 | 2007 | 225 | 0.020 |
Why?
| | Macromolecular Substances | 1 | 2004 | 34 | 0.010 |
Why?
| | Physical Chromosome Mapping | 1 | 2004 | 8 | 0.010 |
Why?
| | tau Proteins | 1 | 2004 | 29 | 0.010 |
Why?
| | Genetic Complementation Test | 1 | 2004 | 48 | 0.010 |
Why?
| | Epitopes | 1 | 2004 | 59 | 0.010 |
Why?
| | Epidermal Growth Factor | 1 | 2004 | 34 | 0.010 |
Why?
| | Cricetulus | 1 | 2004 | 97 | 0.010 |
Why?
| | Catalytic Domain | 1 | 2004 | 58 | 0.010 |
Why?
| | Microtubule-Associated Proteins | 1 | 2004 | 66 | 0.010 |
Why?
| | Mutagenesis | 1 | 2004 | 58 | 0.010 |
Why?
| | Cricetinae | 1 | 2004 | 188 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 2004 | 190 | 0.010 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2004 | 102 | 0.010 |
Why?
| | Receptors, Cell Surface | 1 | 2004 | 116 | 0.010 |
Why?
| | RNA | 1 | 2004 | 163 | 0.010 |
Why?
| | Cell Survival | 1 | 2005 | 589 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 574 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 778 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2004 | 194 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2007 | 1808 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 988 | 0.010 |
Why?
|
|
Alapat's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|